isatuximab

1 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Sarclisa Subcutaneous Formulation Wins CHMP Backing for EU Approval

Sanofi's isatuximab subcutaneous formulation gains European regulatory endorsement for multiple myeloma, offering patients first cancer treatment with portable injector option.
SNYmonoclonal antibodyclinical trials